Tags: Life Sciences
Brussels and Brussels South Charleroi Airports fined for use of thermal cameras
The Belgian Data Protection Authority has fined Brussels Airport and Brussels South Charleroi Airport 200,000 and 100,000 EUR respectively for their use of thermal cameras during the Covid-19 pandemic.
Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
Our speakers Philippe de Jong and Kirian Claeyé discuss the interesting judgment of the General Court in Polpharma v. EMA.
Belgian competition authority hits pharmaceutical wholesalers with cartel fine
Belgian companies active in the pharmaceutical sector at different levels should beware of competition law.
Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?
In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards.
“100g of mealworm please!” – First insect approved under the Novel Foods Regulation
On 3 May 2021, the EU Member states approved “dried yellow mealworms” as a novel food under EU Regulation 2015/2283. According to the applicant, mealworms can be used in a broad range of food products, such as bread, cookies, or pasta.
Webinar video | Life Sciences Session #3: ‘Trop is te veel’: what not to do in case of pricing of medicines?
The COVID-19 pandemic challenges companies and firms worldwide, and requires us all to adopt new proactive approaches. While COVID-19 prevents us from being together, our Life Sciences team takes the initiative to give you short, digestible and regular online Life Sciences Sessions.
Is AstraZeneca obliged to supply the EU with sufficient covid-19 vaccines?
The EU-AstraZeneca agreement imposes a “best reasonable efforts” obligation on AstraZeneca to manufacture and deliver its Covid-19 vaccine doses to the EU. This obligation applies to AstraZeneca’s manufacturing sites not only in the EU, but also in the UK. Although the production issues of the Anglo-Swedish pharma company at its Belgian plant may not necessarily violate its “best reasonable efforts” obligation, it remains highly questionable whether AstraZeneca is allowed under the agreement to prioritise supply of the UK over the EU with its vaccines produced in the UK.
Webinar Video | Life Sciences Session #2: Vaccine liability: what if vaccination goes wrong?
The ongoing vaccination campaign against Covid-19 raises the question of possible side effects and of the potential liability for damages arising from the use of vaccines used against this disease.
Precaution is not enough – CJEU finds that Cannabidiol (CBD) is not a narcotic drug
The legal status of CBD, a naturally occurring compound found in the cannabis plant, is murky. The Court has ruled that CBD is not a narcotic drug and that the principles of free movement apply.
Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products.
TRIS procedure further clarified by the Court of Justice in two recent rulings of 8 October 2020
The Court of Justice of the EU has shed light on Directive 2015/1535 (TRIS) in two recent rulings of 8 October 2020. They explain when a national law triggers the notification procedure and clarify the interrelationship with a notification under another piece of EU law.
Can a parallel importer rebrand generic medicines?
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine?